A multicentered, double-blind, randomized study of Fuzheng syndrome differentiation treatment combined with chemotherapy as the first-line treatment of driver mutation-negative advanced NSCLC

Category Primary study
Registry of TrialsInternational Traditional Medicine Clinical Trial Registry
Year 2020
This article has no abstract
Epistemonikos ID: 6a27812b9b929674134b5be688a0925a1d5238ee
First added on: Apr 11, 2025